Specialty medical injectable drug program, requirements and drug policy updates: Cimerli™ and Skyrizi®
New specialty medical injectable updates and requirements announced.
- All states
Please review the following table to determine changes to our specialty medical injectable drug programs.
Specialty medical injectable drugs added to review at launch
|Drug Name||UnitedHealthcare Commercial||Treatment Uses|
|X||Indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy and myopic choroidal neovascularization.|
Review the UnitedHealthcare Commercial Plan Review at Launch Medication List.
Updates to drug program requirements and drug policies for UnitedHealthcare commercial business effective Nov. 1, 2022
|Drug Name||Treatment Uses||Summary of Changes|
|Skyrizi® – IV formulation
|Used to treat adults with moderate to severe Crohn’s disease.||Add notification/prior authorization and Site of Care.
Note: Subcutaneous self-administered Skyrizi is covered under the pharmacy benefit.
For questions, please contact your broker or UnitedHealthcare representative.
New releases, updates and notifications for a broad spectrum of UnitedHealthcare products and services.
Important, required notices for products, plans, forms and more.
Need-to-know operational announcements for you and your clients.